Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to press releases.
The acquisitions are focused on two therapies: gildeuretinol (ALK-001, Alkeus Pharmaceuticals) and IRX-101 (iRenix Medical). Gildeuretinol is an investigational once-daily oral therapy for the treatment of Stargardt disease designed to reduce damage to the retina caused by the accumulation of toxic dimers, while IRX-101 is an investigational ocular antiseptic designed to reduce pain and corneal toxicity after intravitreal injections, according to